Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 13:16:463.
doi: 10.1186/s12885-016-2529-1.

Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study

Li-Han Hsu  1   2   3 , Pei-Chi Hsu  4 , Tien-Ling Liao  4 , An-Chen Feng  5 , Nei-Min Chu  6 , Shu-Huei Kao  7   8
Affiliations

Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study

Li-Han Hsu et al. BMC Cancer. .

Abstract

Background: Rapidly growing cancer cells secrete growth-promoting polypeptides and have increased proteolytic activity, contributing to tumor progression and metastasis. Their presentation in malignant pleural effusion (MPE) and their predictive value for the outcome of pleurodesis and survival were studied.

Methods: Between February 2011 and March 2012, MPE samples were prospectively collected from 61 patients. Twenty-five patients with non-malignant pleural effusion in the same period were included as controls. Pleural fluid osteopontin (OPN), vascular endothelial growth factor (VEGF), and urokinase-type plasminogen activator (uPA) concentrations were measured.

Results: Patients with MPE had higher pleural fluid OPN, VEGF, and uPA concentrations than those with non-malignant pleural effusion, but only differences in VEGF were statistically significant (p = 0.045). Patients with distant metastases had significantly elevated pleural fluid VEGF concentrations than those without (p = 0.004). Pleural fluid OPN, VEGF, and uPA concentrations were positively correlated in most patients. However, there was no significant difference in pleural fluid OPN, VEGF, and uPA concentrations between patients with successful pleurodesis and those without. There was also no significant difference in cancer-specific survival between sub-groups with higher and lower pleural fluid OPN, VEGF, or uPA concentrations. Patients with successful pleurodesis had significantly longer cancer-specific survival than those without (p = 0.015).

Conclusions: Pleural fluid OPN, VEGF, and uPA concentrations are elevated in MPE but are not satisfactory predictors of pleurodesis outcome or survival. Patients with higher pleural fluid VEGF concentration have higher risk of distant metastasis. Evaluating the benefits of therapy targeting the VEGF pathway in these patients warrants further studies.

Keywords: Malignant pleural effusion; Osteopontin; Pleurodesis; Survival; Urokinase-type plasminogen activator; Vascular endothelial growth factor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patients with successful pleurodesis had significantly longer cancer-specific survival than those without
See this image and copyright information in PMC

References

    1. American Thoracic Society Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(5):1987–2001. doi: 10.1164/ajrccm.162.5.ats8-00. - DOI - PubMed
    1. Light RW. Pleural effusions related to metastatic malignancies. In: Light RW, editor. Pleural diseases. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 108–134.
    1. Rodriguez-Panadero F, Montes-Worboys A. Mechanism of pleurodesis. Respiration. 2012;83(2):91–98. doi: 10.1159/000335419. - DOI - PubMed
    1. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989;49(10):2533–2553. - PubMed
    1. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16(2):79–87. doi: 10.1016/j.tcb.2005.12.005. - DOI - PubMed

Publication types

Substances